Evidence map›Paper›PMID 40644620›Full record

ArticleRheumatology (Oxford, England)2025

'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.

Hana Sabanovic, John D Pauling, Murray Baron, Laurence Clemens, Francesco Del Galdo, Christopher P Denton, Oliver Distler, Tracy Frech, Anna-Maria Hoffmann-Vold, Marie Hudson and 10 more

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hana SabanovicCentre for Health Policy, School of Population and Global Health, University of Melbourne, Parkville, Australia.ORCID 0000-0002-2759-8781
John D PaulingDepartment of Rheumatology, North Bristol NHS Trust, Bristol, UK.
Murray BaronDivision of Rheumatology, Jewish General Hospital, McGill University, Montreal, Canada.
Laurence ClemensDepartment of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia.
Francesco Del GaldoLeeds Institute of Rheumatic and Musculoskeletal Medicine, LIRMM, Leeds, UK.ORCID 0000-0002-8528-2283
Christopher P DentonCentre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, London, UK.ORCID 0000-0003-3975-8938
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0546-8310
Tracy FrechDepartment of Medicine, Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Tennessee Valley Healthcare System for Veterans Affairs, Nashville, USA.ORCID 0000-0002-5472-3840
Anna-Maria Hoffmann-VoldDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6467-7422
Marie HudsonDivision of Rheumatology, Jewish General Hospital, McGill University, Montreal, Canada.
Dinesh KhannaUniversity of Michigan Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, USA.ORCID 0000-0003-1412-4453
Nancy MaltezDepartment of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Thomas A MedsgerUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Peter A MerkelDivision of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, USA.ORCID 0000-0001-9284-7345
Mandana NikpourSydney Musculoskeletal Research Flagship Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Janet PopeSchulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.ORCID 0000-0003-1479-5302
Virginia D SteenDivision of Rheumatology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA.
Wendy StevensDepartment of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia.
Elizabeth R VolkmannDivision of Rheumatology, Department of Medicine, University of California, Los Angeles, Los Angeles, USA.ORCID 0000-0003-3750-6569
Laura RossDepartment of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia.ORCID 0000-0003-4636-729X

Funding

AstraZenecaGrant-in-Aid from Arthritis AustraliaScleroderma Clinical Trials Consortium
6 · The paper itself

Abstract

objectivesPhysician global assessments (PhyGAs) are commonly performed in randomized controlled trials (RCTs) in SSc. However, there is no single PhyGA applied across RCTs. We performed an exploratory qualitative study to explore perceptions of the PhyGA, its role in RCTs and how physicians perform their own assessment.

methodsParticipants with expertise in the clinical assessment and, or actively involved in research on SSc were invited to participate. Participants were asked to define disease constructs of activity, damage, severity, and overall health, and to describe how they perform a PhyGA and their perception of what a PhyGA should assess. Interview transcripts were analysed using deductive and inductive thematic analysis.

resultsEighteen rheumatologists and one patient research partner were interviewed. Four major themes were identified: (i) physician uncertainty; (ii) variation in the conduct of a PhyGA; (iii) physician efforts to improve PhyGA consistency; (iv) utility of a PhyGA. Most participants felt a PhyGA should assess changeable aspects of SSc, commonly conceived of as disease activity. There was considerable uncertainty about the optimal method for assessing disease activity. Participants were uncertain about their own methods of performing a PhyGA, and variability in the application of the instrument was identified. Despite these limitations, physicians generally agreed that the PhyGA is useful and can assess unquantifiable aspects of SSc.

conclusionWe identified significant heterogeneity in the approach to PhyGAs in SSc. This variation was considered a limitation of the PhyGA. Overall, a PhyGA was viewed as a useful instrument that can aid the assessment of treatment response in RCTs.

Indexed as

Attitude of Health PersonnelRandomized Controlled Trials as TopicRheumatologistsScleroderma, SystemicFemaleHumansMaleMiddle AgedQualitative ResearchSeverity of Illness Indexclinical trialsglobal assessmentoutcome measuresphysician assessmentsystemic sclerosis

Identifiers

PMID40644620
PMCPMC12596065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.